Year: 2025
Type: article
Abstract: Intratracheal administration of PROTAC 13 induced dose-dependent, local BRD4 degradation in the mouse lung, sparing BRD4 levels in the spleen.
Source: RSC Medicinal Chemistry
DOI: 10.1039/d5md00173k
Authors: Martin Hemmerling, Jianming Liu, Antonio Piras, Rikard Pehrson, Ulf Hedström, Carlo Cassani, Beatrice Ranieri, Karolina Kwapień, Karin Ribbing, Cecilia Forss, Oliwia Slettengren, Frederik Eisele, Mei Ding, Pia Hansson, Anna Novén, Markus Nordberg, Hyunsoo Park, Annica Jarke, Lisa-Catherine Rosenbaum, Jesper Malmberg, Annika Borde, Lassina Badolo, Madeleine Engsevi, Johan Jirholt, Perla Breccia, Stefan Schiesser, Lena Ripa, Werngard Czechtizky
Institutions: AstraZeneca (Sweden), AstraZeneca (United Kingdom)
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
Funders: AstraZeneca, Pharmaron
OpenAlex ID: W4409622862